Navigation Links
LA BioMed researchers report on promising new therapy for devastating genetic disorder
Date:2/12/2014

LOS ANGELES (Feb. 12, 2014) A promising new therapy has for the first time reduced damage to the brain that can be caused by Sanfilippo B (MPS IIIB), a rare and devastating genetic disease, Los Angeles Biomedical Research Institute (LA BioMed) researchers will report today in a presentation at the Lysosomal Disease Network's 10th Annual WORLD Symposium.

Sanfilippo B syndrome is a lysosomal storage disease belonging to the group of mucopolysaccharidoses (MPS) that is characterized by severe and rapid intellectual deterioration. LA BioMed pioneered the research that led to the first enzyme replacement therapy for MPS I, Aldurazyme, which has saved hundreds of lives in the nearly 11 years since it was approved by the Food and Drug Administration.

LA BioMed's MPS Research Laboratory reported the results of its latest study for treating Sanfilippo B syndrome in a disease model that employed recombinant human "NAGLU-IGF2" (a novel fusion protein of alpha-N-acetyglucosaminidase, or NAGLU, coupled to a peptide derived from the insulin-like growth factor, IGF2). The fusion protein was produced by BioMarin Pharmaceutical Inc.

LA BioMed researcher Shih-hsin Kan reported that the laboratory's tests found NAGLU-IGF2 is taken up by neurons in the disease model, which then reduces brain damage by reversing heparan sulfate storage one of the causes of damage to the brain in patients with Sanfilippo B syndrome. The researchers concluded that NAGLU-IGF2 can be the basis for enzyme replacement therapy for Sanfilippo B syndrome.

"This is an exciting new development that needs to be examined further to determine its effectiveness in patients with Sanfilippo B syndrome who currently have no therapies available to reduce the damage to their brains," said Patricia Dickson, MD, director of the MPS Research Laboratory at LA BioMed. "We look forward to continuing our partnership with BioMarin in developing therapies for MPS."

BioMarin announced Tuesday that it has developed BMN 250, a manufactured form of NAGLU-IGF2, for the treatment of Sanfilippo B syndrome and expects to initiate clinical studies with BMN 250 in mid-2015.


'/>"/>

Contact: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Pitts Center for Medical Innovation announces pilot funding for biomedical technology
2. New biomedical diagnostics using personalized 3-D imaging
3. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
4. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
5. A New Player In Biomedical Equipment Opens Headquarters in San Diego
6. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
7. CHI and PwC US Release 2014 California Biomedical Industry Report
8. New materials with potential biomedical applications
9. California Healthcare Institute to Release 2014 California Biomedical Industry Report
10. Animal, human health benefits anticipated from universitys premier biomedical instrument
11. MU receives $1.1 million training grant to increase diversity in biomedical sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... welcomes you to stop by for a visit this week at HIMSS 2017 ... and executives from around the globe. Sensogram will be featured in the conference’s ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism ... event at Chuck E. Cheese’s locations throughout New England, New York and New Jersey ... to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... ... ... a set of 30 glitch distortion logo reveals made exclusively for Final Cut Pro ... reveal in just a few clicks of a mouse. Customizable glitch style effects give Final ... presets to add a uniquely animated logo to any photos or videos. Its never been ...
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive ... Dr. Brian Seese leads the practice as a skilled and highly credentialed dentist who ... by Seese serves patients of all ages with excellence in general, restorative, and ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 2017  Henry Schein, Inc. (Nasdaq: HSIC), the ... and services to office-based dental, animal health, ... has entered into an agreement to acquire ... U.S. distributor of anesthesia and surgical supplies ... SAS offers controlled and non-controlled pharmaceuticals, as ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017  This report analyzes ... US$ Million. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html ... the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:2/20/2017)... , Feb. 20, 2017 Research and ... Tourism Market: Insights, Opportunity, Analysis, Market Shares & Forecast 2017 - ... ... to reach nearly USD 2 Billion by the year end of ... 2022. Market growth can be attributed to factors ...
Breaking Medicine Technology: